Genmab EBITDA 2019-2022 | GMAB

Genmab annual and quarterly EBITDA history from 2019 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Genmab EBITDA for the quarter ending March 31, 2022 was $0.078B, a 10.12% decline year-over-year.
  • Genmab EBITDA for the twelve months ending March 31, 2022 was $0.471B, a 54.8% decline year-over-year.
  • Genmab 2021 annual EBITDA was $0.52B, a 48.39% decline from 2020.
  • Genmab 2020 annual EBITDA was $1.007B, a 141.87% increase from 2019.
  • Genmab 2019 annual EBITDA was $0.416B, a 79.03% increase from 2018.
Genmab Annual EBITDA
(Millions of US $)
2021 $520
2020 $1,007
2019 $416
2018 $233
Genmab Quarterly EBITDA
(Millions of US $)
2022-03-31 $78
2021-12-31 $125
2021-09-30 $141
2021-06-30 $128
2021-03-31 $86
2020-12-31 $158
2020-09-30 $135
2020-06-30 $664
2020-03-31 $10
2019-12-31 $443
2019-09-30 $52
2019-06-30 $21
2019-03-31 $90
2018-12-31 $196
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $20.069B $1.349B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00